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A B S T R A C T
Background
Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson’s disease with dementia (PDD) and
dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on
the basis of whether or not parkinsonism precedes dementia by more than a year. Patients with both conditions have particularly severe
deficits in cortical levels of the neurotransmitter acetylcholine. Therefore, blocking its breakdown using cholinesterase inhibitors may
lead to clinical improvement.
Objectives
To assess the efficacy, safety and tolerability of cholinesterase inhibitors in dementia with Lewy bodies (DLB), Parkinson’s disease
with dementia (PDD), and cognitive impairment in Parkinson’s disease falling short of dementia (CIND-PD) (considered as separate
phenomena and also grouped together as Lewy body disease).
Search methods
The trials were identified from a search of ALOIS, the Specialised Register of the Cochrane Dementia and Cognitive Improvement
Group (on 30 August 2011) using the search terms Lewy, Parkinson, PDD, DLB, LBD. This register consists of records from major
healthcare databases (MEDLINE, EMBASE, PsycINFO, CINAHL) and many ongoing trial databases and is updated regularly.
Reference lists of relevant studies were searched for additional trials.
Selection criteria
Randomised, double-blind, placebo-controlled trials assessing the efficacy of treatment with cholinesterase inhibitors in DLB, PDD
and cognitive impairment in Parkinson’s disease (CIND-PD).
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Data collection and analysis
Data were extracted from published reports by one review author (MR). The data for each ’condition’ (that is DLB, PDD or CIND-
PD) were considered separately and, where possible, also pooled together. Statistical analysis was conducted using Review Manager
version 5.0.
Main results
Six trials met the inclusion criteria for this review, in which a total of 1236 participants were randomised. Four of the trials were of a
parallel group design and two cross-over trials were included. Four of the trials included participants with a diagnosis of Parkinson’s
disease with dementia (Aarsland 2002a; Dubois 2007; Emre 2004; Ravina 2005), of which Dubois 2007 remains unpublished. Leroi
2004 included patients with cognitive impairment and Parkinson’s disease (both with and without dementia). Patients with dementia
with Lewy bodies (DLB) were included in only one of the trials (McKeith 2000).
For global assessment, three trials comparing cholinesterase inhibitor treatment to placebo in PDD (Aarsland 2002a; Emre 2004;
Ravina 2005) reported a difference in the Alzheimer’sDisease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
score of -0.38, favouring the cholinesterase inhibitors (95% CI -0.56 to -0.24, P < 0.0001).
For cognitive function, a pooled estimate of the effect of cholinesterase inhibitors on cognitive function measures was consistent with
the presence of a therapeutic benefit (standardised mean difference (SMD) -0.34, 95% CI -0.46 to -0.23, P < 0.00001). There was
evidence of a positive effect of cholinesterase inhibitors on the Mini-Mental State Examination (MMSE) in patients with PDD (WMD
1.09, 95% CI 0.45 to 1.73, P = 0.0008) and in the single PDD and CIND-PD trial (WMD 1.05, 95% CI 0.42 to 1.68, P = 0.01)
but not in the single DLB trial.
For behavioural disturbance, analysis of the pooled continuous data relating to behavioural disturbance rating scales favoured treatment
with cholinesterase inhibitors (SMD -0.20, 95% CI -0.36 to -0.04, P = 0.01).
For activities of daily living, combined data for the ADCS and the Unified Parkinson’s Disease Rating Scale (UPDRS) activities of daily
living rating scales favoured treatment with cholinesterase inhibitors (SMD -0.20, 95% CI -0.38 to -0.02, P = 0.03).
For safety and tolerability, those taking a cholinesterase inhibitor were more likely to experience an adverse event (318/452 versus 668/
842; odds ratio (OR) 1.64, 95% CI 1.26 to 2.15, P = 0.0003) and to drop out (128/465 versus 45/279; OR 1.94, 95% CI 1.33 to
2.84, P = 0.0006). Adverse events were more common amongst those taking rivastigmine (357/421 versus 173/240; OR 2.28, 95%
CI 1.53 to 3.38, P < 0.0001) but not those taking donepezil (311/421 versus 145/212; OR 1.24, 95% CI 0.86 to 1.80, P = 0.25).
Parkinsonian symptoms in particular tremor (64/739 versus 12/352; OR 2.71, 95% CI 1.44 to 5.09, P = 0.002), but not falls (P =
0.39), were reported more commonly in the treatment group but this did not have a significant impact on the UPDRS (total and
motor) scores (P = 0.71). Fewer deaths occurred in the treatment group than in the placebo group (4/465 versus 9/279; OR 0.28, 95%
CI 0.09 to 0.84, P = 0.03).
Authors’ conclusions
The currently available evidence supports the use of cholinesterase inhibitors in patients with PDD, with a positive impact on global
assessment, cognitive function, behavioural disturbance and activities of daily living rating scales. The effect in DLB remains unclear.
There is no current disaggregated evidence to support their use in CIND-PD.
P L A I N L A N G U A G E S U M M A R Y
Cholinesterase inhibitors are beneficial for people with Parkinson’s disease and dementia
The clinical features of dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) have much in common.
As patients with DLB and PDD have particularly severe deficits in cortical levels of the neurotransmitter acetylcholine, blocking
its breakdown using a group of chemicals known as cholinesterase inhibitors may lead to clinical improvement. Six trials showed a
statistically significant improvement in global assessment, cognitive function, behavioural disturbance and activities of daily living rating
scales in PDD and cognitive impairment in Parkinson’s disease (CIND-PD) patients treated with cholinesterase inhibitors. There was
no current disaggregated evidence to support their use in CIND-PD. No statistically significant improvement was observed in patients
with DLB treated with cholinesterase inhibitors and further trials are necessary to clarify the effect of cholinesterase inhibitors in this
patient group.
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B A C K G R O U N D
’When you’ve seen one patient with dementia, you’ve seen one
patient with dementia’. This commonplace observation about the
wide heterogeneity in the clinical presentation of dementia raises
the possibility that there may be useful diagnostic subdivisions.
The most common cause of dementia is Alzheimer’s disease but
there are several others, of which dementia with Lewy bodies is
arguably the second most common.
Lewy bodies are the defining pathological feature of idiopathic
Parkinson’s disease. These inclusion bodies are found in the cy-
toplasm of cells of a wide variety of subcortical nuclei, including
those of monoaminergic neurons. They are more likely to occur
in cortical neurons in patients with Parkinson’s disease when the
patients also have dementia. A defining constituent is fibrillar ag-
gregates of alpha-synuclein, a presynaptic protein involved in vesi-
cle formation (Lee 2006). One current theory about why Lewy
bodies form is that the cellular mechanisms for degrading and dis-
posing of intracellular protein fragments (proteasomes) are dys-
functional (Olanow 2006). In epidemiological studies, up to 30%
of those people with dementia have Lewy bodies (Zaccai 2005).
The rate of dementia in clinical Parkinson’s disease (24% to 31%)
(Aarsland 2005) is at least two to five times that expected in age
matched controls. Longitudinal studies suggest that most patients
with Parkinson’s disease who survive will eventually develop de-
mentia (Aarsland 2003).
Scope of this review
Previous Cochrane reviews have considered the use of
cholinesterase inhibitors in both Parkinson’s disease with dementia
(PDD) (Maidment 2006) and dementia with Lewy bodies (DLB)
(Wild 2003). The clinical features of DLB and PDD have much
in common. There is some convergence of opinion that DLB and
PDD may be the same condition, but the matter is not fully re-
solved because DLB and PDD have slightly different neuropatho-
logical correlates (Ballard 2006; Burn 2006; McKeith 2005).
The diagnosis of PDD rests on the occurrence of formally diag-
nosed Parkinson’s disease followed at least 12 months later by de-
mentia (with no other apparent cause identified). Most patients
with Parkinson’s disease have at least subtle deficits in neuropsy-
chological function, typically affecting visuospatial and sometimes
executive function. Inmany cases this does not cause problems and
is only apparent on detailed specialist evaluation. Cognitive im-
pairment that is clinically significant typically involves more clear-
cut deficits in these areas but also tends to affect attention. These
are also the three areas of function (visuospatial, executive, atten-
tion) prominently affected early in patients labelled DLB. Mem-
ory function may be affected late in the process. Dementia is more
likely to occur in those in whom the Parkinson’s disease develops
later, tends to be of the postural instability-gait disorder subtype
and to be associated with visual hallucinations when treated with
L-dopamine (L-DOPA). The development of dementia associated
with Parkinson’s disease increases caregiver distress, nursing home
requirements and mortality, twofold. It also reduces quality of life
(Bedard 2003; Burn 2003). Similarly, parkinsonism in Alzheimer’s
disease increases the cost of care (Bostrom 2006).
The formal distinction between PDD and early cognitive impair-
ment in Parkinson’s disease rests on the definition of dementia.
Dementia is defined as occurring when cognitive impairment is of
a severity or type such that it interferes with day-to-day occupa-
tional and social functioning.However, it is particularly difficult to
judge reliably whether any impairment in function in Parkinson’s
disease is due to cognitive decline or alternatively to the motor,
mood or personality changes which may occur. In this review, we
have therefore also included a further group of patients, patients
who have Parkinson’s disease and who have clinically significant
cognitive impairment but in whom the diagnosis of dementia has
not been formally established. This is analogous to the ’Cogni-
tive Impairment, Not Dementia (CIND)’ category and will be
termed ’CIND-PD’. This approach is consistent with the current
version of the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-IV-R) criteria (294.1x).
The diagnosis of ’probable DLB’ is more complex than that for
PDD. It depends on the presence of two of: persistent visual hal-
lucinations; fluctuations in cognitive and functional ability; and
parkinsonism. If parkinsonian symptoms are part of the picture,
dementia should have occurred within 12 months of the onset
of the parkinsonian symptoms. Additionally, ’probable DLB’ can
also be diagnosed if just one of these original features is present plus
one of the following: severe sensitivity to neuroleptics; rapid eye
movement (REM) sleep behaviour disorder; or evidence of stri-
atal dopamine transporter protein loss on neuroimaging (McKeith
2005).
Other symptoms that support the diagnosis but are of less clear-
cut diagnostic value are repeated falls, syncope, transient distur-
bances of consciousness, severe autonomic dysfunction (for exam-
ple orthostatic hypotension), urinary incontinence, systematised
delusions, non-visual hallucinations, depression, relative preserva-
tion of medial temporal lobe structures on a computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) scan, generalized
low uptake on single-photon emission CT (SPECT) or positron
emission tomography (PET) perfusion scanwith reduced occipital
activity, abnormal (low uptake) [123I]meta-iodobenzylguanidine
(MIBG) myocardial scintigraphy and prominent slow wave activ-
ity on electroencephalography (EEG)with temporal lobe transient
sharp waves. Olfactory function may also be impaired (Williams
2009).
The distinction between PDD and DLB was introduced in 1995 (
McKeith 1996). It was recognised at the time that these conditions
had much in common, and that the cut-off period of 12 months
was arbitrary. The distinction was in part driven by the fact that,
in some health systems, patients who develop Parkinson’s disease
first tend to see neurologists whereas those who develop cognitive
impairment first tend to see psychiatrists. It also reflected in the
fact that regulators can only issue licenses for drugs where a claim is
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made for the drug in a clearly defined (and accepted) condition. In
the third revision of the consensus statement (McKeith 2005), the
DLB consortium has suggested that a generic term such as Lewy
body disease (LB disease) may be helpful when PDD and DLB are
considered together, but that in clinical situations the terms PDD
and DLB should be retained as they differentiate between whether
symptoms of dementia occur before or after those of Parkinson’s
disease.
By considering the results of treatment trials for PDD, DLB and
CIND-PD, both separately and together, it may be possible to see
whether there is any difference in the response to cholinesterase
inhibitors in these conditions.
Rationale for cholinesterase inhibitors
Lewy bodies occur in the dopamine-producing cells of the sub-
stantia nigra, where their presence is associated with the move-
ment problems of Parkinson’s disease. However, alpha-synuclein
aggregation occurs in many other brain areas too and the extent
of this may correlate with dementia (Braak 2006). A broad cor-
relation can also be made between the areas affected and spe-
cific clinical symptoms: cholinergic deficits and attention or mem-
ory (Nakano 1984); serotonergic deficits and depression (Jellinger
1994); dopaminergic deficits and visuospatial or executive symp-
toms (Dubois 1997); and cortical LBs and executive function im-
pairment. In his original description, Frederick Lewy actually put
more emphasis on the occurrence of LBs in the large cells of the
substantia innominata (now named the nucleus basalis of Myen-
ert). We now know that these cells synthesise acetylcholine and
project widely to cortical areas. This nucleus is also affected by
the neurofibrillary tangles of Alzheimer’s disease. Patients with
DLB or PDD have particularly severe deficits in cortical levels
of acetylcholine and its enzyme for synthesis, even exceeding the
deficits of patients with just Alzheimer’s disease (AD) pathology
(Perry 1994). The key neuropathological defect that is targeted
by cholinesterase inhibitors is therefore present in AD, PDD and
DLB. Moreover, the lower cholinergic functioning in DLB and
PDD may indicate a greater potential improvement from these
drugs than that seen in AD. Since there are fewer neurofibrillary
tangles and neuritic plaques and less neuronal loss in DLB than
AD (Lippa 1998), it is possible that cortical neurons in DLB are
more viable than those in AD and could be more responsive to
cholinergic stimulation. Similarly, because those patients with vi-
sual hallucinations and more profound deficits in attention tend
to have worse cholinergic deficits, the presence of this symptom
may be a predictor of treatment response.
The combination of psychotic features and parkinsonism which
occur in DLB and PDD can be particularly difficult to manage.
Antipsychotic drugs used to treat hallucinations, delusions and
agitation can dramatically worsen cognitive and extrapyramidal
symptoms andmay lead to severe, and even fatal, neuroleptic sensi-
tivity (McKeith 1992). Conversely, L-DOPA treatment of parkin-
sonism can exacerbate the psychosis. Given that anticholinergic
agents are effective in reducing symptoms of tremor in PD, there
are theoretical reasons why ’pro-cholinergic’ interventions such
as cholinesterase inhibitors, which act to reduce breakdown of
acetylcholine, might worsen the motor symptoms of PD (Thomas
2005).
Drug licensing
To date, rivastigmine is the only cholinesterase inhibitor that
is licensed for the treatment of mild to moderate dementia in
Alzheimer’s disease and Parkinson’s disease in the UK (Medicines
and Healthcare products Regulatory Agency) and the USA (Fed-
eral Drug Authority). The use of donepezil and galantamine is
only licensed in mild to moderate Alzkeimer’s disease.
O B J E C T I V E S
To assess the efficacy, safety and tolerability of cholinesterase in-
hibitors in patients with dementia with Lewy bodies (LB), Parkin-
son’s disease with dementia and cognitive impairment in Parkin-
son’s disease (considered as a separate phenomena and also grouped
together as LB disease).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, double-blind, placebo-controlled trials assessing the
efficacy of treatment with cholinesterase inhibitors in DLB, PDD
and cognitive impairment in Parkinson’s disease (CIND-PD).
Types of participants
All patients with either DLB or PDD or cognitive impairment
in Parkinson’s disease. Coexisting Alzheimer’s disease was not an
exclusion.
Types of interventions
Any studies comparing any of the current cholinesterase inhibitors
(donepezil, galantamine, rivastigmine, tacrine) at any dose, taken
over any length of time, against placebo.
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Types of outcome measures
Outcome measures included the following.
1. Neuropsychiatric features (e.g. psychiatric symptoms, be-
havioural features); subgroup analysis of those with and without
visual hallucinations.
2.Cognitive function; subgroup analysis of thosewith andwithout
attentional deficits.
3. Activities of daily living.
4. Global assessments.
5.Quality of life, e.g. includingmaintenance of social functioning.
6. Effect on carers.
7. Institutionalization.
8. Effect on Parkinsonian features (e.g. tremor, rigidity).
9. Acceptability of treatment, as indicated by patient or carer as-
sessment or by measurement of withdrawal from trials, or both.
10. Safety, as measured by severity and frequency of side effects
and adverse events.
11. Deaths, including deaths during trials and time to death.
12. Heath economics.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois),
the Cochrane Dementia and Cognitive Improvement Group Spe-
cialised Register (on 30August 2011). The search terms used were:
PDD, parkinson, LBD, DLB, lewy.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy people. The studies
are identified from:
1. monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS;
2. monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register plus
others);
3. a quarterly search of The Cochrane Library’s Central
Register of Controlled Trials (CENTRAL);
4. six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ‘methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above, to cover the timeframe from the last searches performed for
ALOIS, to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
The latest search (August 2011) retrieved a total of 240 results.
After a first assessment and de-duplication of these results the
authors were left with 50 references to further assess.
Searching other resources
Reference lists of relevant studies were searched for additional tri-
als.
Data collection and analysis
Selection of studies
Two review authors (MR, RMcS) independently selected trials for
relevance using defined criteria in the current Cochrane Handbook
for Systematic Reviews of Interventions.
Asessment of methodological quality
Review authors (MR, RMcS) independently assessed the quality
of the trials according to the criteria given in the Cochrane Hand-
book. Where the review authors (MR, RMcS) identified bias and
agreed that it was significant, trials were excluded from further
analysis; reasons for such exclusion were given.
Data extraction
Data were extracted from the published reports (MR). Any uncer-
tainty over inclusion or exclusion of a trial, methodological quality
or data extraction were settled by discussion with a second review
author (RMcS) who had previously extracted data in an earlier
draft of this review.
The summary statistics required for each trial and each outcome
for continuous data are the mean change from baseline, the stan-
dard error of themean change, and the number of patients for each
treatment group at each assessment. Where changes from baseline
were not reported, the mean, standard deviation and the number
of patients for each treatment group at the final time point were
extracted, if available. Results from the donepezil groups in a study
which compared two doses of donepezil were combined (Dubois
2007). For binary data the numbers in each treatment group and
the numbers experiencing the outcome of interest were sought.
The baseline assessment was defined as the latest available assess-
ment prior to randomisation, but no longer than two months ear-
lier. Data from titration phases prior to the randomised phase, or
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from open-label follow-up periods, were not used to assess safety
or efficacy because patients were not randomised or treatments
concealed.
Analysis plan
Data for trials in each ’condition’ (that is PDD, DLB, CIND-
PD) were considered separately on each outcome measure. Data
for the conditions were also combined. It was intended that data
for the three conditions would be considered both separately and
combined together. Results were also analysed according to the
cholinesterase used and the duration of the trial. Results were
examined to establish whether any heterogeneity was explicable on
the basis of the condition. Where there was no heterogeneity, then
the focus in the text was determined by the number and quality
of trials. Where the heterogeneity of results was high, as indicated
by I² > 40%, this was reported in the text.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Six trials met the inclusion criteria for this review and 1236 partic-
ipants were randomised in total. Four of the trials were of a parallel
group design and two were cross-over trials.
Participants
All participants were aged 18 years and over, with both males and
females included in all of the trials. Four of the trials included
participants with a diagnosis of Parkinson’s disease with dementia
(Aarsland 2002a; Dubois 2007; Emre 2004; Ravina 2005), of
which Dubois 2007 remains unpublished. Leroi 2004 included
patients with either Parkinson’s disease with dementia or cognitive
impairment in Parkinson’s disease. Patients with dementia with
Lewy Bodies were included in only one of the trials (McKeith
2000).
Setting
The trials were all conducted in the outpatient population. Three
of the trials were multicenter studies (Dubois 2007; McKeith
2000; Emre 2004). Two of the trials took place in the United
States of America (Leroi 2004; Ravina 2005), with the remaining
trial taking place in Norway (Aarsland 2002a).
Intervention
Two of the trials compared the use of oral rivastigmine, up to 12
mg daily, with the use of placebo (Emre 2004; McKeith 2000).
The remaining trials compared the use of oral donepezil to oral
placebo. Three of the trials (Aarsland 2002a; Leroi 2004; Ravina
2005) studied donepezil at the highest tolerated dose (up to 10
mg daily). Dubois 2007 compared the use of donepezil at two
different doses (either 5 mg or 10 mg) to placebo.
Duration
Four of the trials were 18 weeks or more in duration (Dubois
2007; Emre 2004; Leroi 2004; McKeith 2000). The remaining
two trials lasted 10 weeks (Aarsland 2002a; Ravina 2005).
Outcome measures
• Global assessment
1. The Alzheimer’s Disease Cooperative Study Clinician’s
Global Impression of Change (ADCS-CGIC) scale (Schneider
1997) is a 7-point scale providing a global rating of patient
function in four areas: general, cognitive, behaviour and
activities of daily living. Assessments should be performed by the
same clinician with input from the patient and the caregiver.
• Cognitive function
1. Mini-Mental State Examination (MMSE) (Folstein 1975)
evaluates cognition in five areas: orientation, immediate recall,
attention and calculation, delayed recall, and language. Test
scores range from 0 (severe impairment) to 30 (normal).
2. The cognitive part of the Alzheimer’s Disease Assessment
Scale (ADAS-Cog) (Rosen 1984) comprises 11 individual
sections testing spoken language, recall of test instructions, word
finding difficulty, following commands, naming objects,
construction drawing, ideational praxis, orientation, word recall
and word recognition. The maximum score is 70, with higher
scores representing greater impairment.
3. The Mattis Dementia Rating Scale (MDRS) (Mattis 1988)
assesses cognitive function on five subscales: attention, initiation-
perseveration, construction, conceptualisation and memory.
4. The Cognitive Drug Research (CDR) Computerized
Assessment System (Simpson 1991) power of attention tests
evaluate simple and complex reaction times and digit vigilance.
Scores are measured in milliseconds with higher scores indicating
a worse performance.
5. The Delis-Kaplan Executive Function System (D-KEFS)
Verbal Fluency test (Delis 2001) requires patients to produce as
many words starting with a particular letter as they can in one
minute. Higher scores indicate better performance.
6. The Ten Point Clock-Drawing test (Manos 1994) is used as
a measure of spatial dysfunction and neglect. Scores range from 0
to 10 with higher results indicating better performance.
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7. Brief test of attention (BTA) (Schretlen 1997) is an
auditory perception task that measures divided attention in the
verbal-linguistic system. Raw scores range from 0 (severe
impairment) to 20 (normal).
8. The Trail Making Test (TMT) (Reitan 1958) tests visual
attention and task switching. It is divided into two parts: part A,
containing only numbers; and part B, in which the participant
must alternate between numbers and letters. The time to
complete the test is used as the performance measure.
9. The Verbal Fluency test (Barr 1996) assesses the efficiency
of verbal retrieval, short-term memory and cognitive flexibility
by asking the participant to name as many animals as he or she
can in 60 seconds.
10. Hopkins Verbal Learning Test (Brandt 2001) is a brief
verbal learning and memory test.
11. Developmental Test of Visual-Motor Integration (VMI)
(Beery 1989) consists of copying 24 geometric forms. A higher
score indicates a better performance.
• Behavioural disturbance
1. The 10-item Neuropsychiatric Inventory (NPI) (Cummings
1994) is a relatively brief interview that assesses 10 types of
behavioural disturbance: delusions, hallucinations, dysphoria,
anxiety, agitation or aggression, euphoria, disinhibition,
irritability or lability, apathy and aberrant motor behaviour.
Scores range from 0 (normal) to 120 (severely disturbed).
2. The Brief Psychiatric Rating Scale (BPRS) (Overall 1962) is
used to measure psychiatric symptoms such as depression,
anxiety, hallucinations and unusual behaviour. Each symptom is
rated 1 to 7 according to severity.
• Activities of daily living (ADL)
1. The Alzheimer’s Disease Cooperative Study activities of
daily living inventory (ADCS-ADL) (Galasko 1997) is a scale for
basic and complex abilities that has been validated in patients
with dementia. The highest score is 78 and implies no
impairment.
2. Unfied Parkinson’s Disease Rating Scale (UPDRS) -
Activities of Daily Living is a subscale of the UPDRS (see below).
• Safety and tolerability
1. The Unified Parkinson’s Disease Rating Scale (UPDRS)
(Fahn 1987) is used to follow the longitudinal course of
Parkinson’s disease. It is divided into five sections: evaluation of
mentation, behaviour and mood; self evaluation of activities of
daily living; clinician-scored motor evaluation, severity of
Parkinson’s disease (Hoehn and Yahr); and the Schwab and
England ADL scale. Higher scores imply more severe disease.
Risk of bias in included studies
Allocation
Aarsland 2002a and McKeith 2000 provided details of adequate
sequence generation and concealment. Emre 2004 provided good
details of sequence generation but did not specify methods used
to maintain concealment of allocation, whilst Leroi 2004 did not
discuss the randomisation procedures followed. Neither Dubois
2007 nor Ravina 2005 provided any details of the allocation pro-
cedure.
Blinding
All the trials described the use of ’double-blind’ methods but none
of them described how this was achieved.
Reporting of withdrawals or dropouts
Dubois 2007 did not disclose whether any of the participants with-
drew or dropped out during the study. All other trials reported
the numbers of withdrawals and dropouts but only McKeith 2000
included all of these in the final analysis. Aarsland 2002a, Emre
2004 and Leroi 2004 only included participants that received at
least one dose of the study medication and had at least one mea-
surement at baseline and at one other time point in the efficacy
analysis, using the last observation carried forward. One study
(Ravina 2005) specified that participants had to have at least one
visit in the second period to be included in the efficacy analysis.
Three participants were included in the safety but not the efficacy
analysis as data from both periods were required for the cross-over
analysis.
Selective reporting
Aarsland 2002a only published primary outcomes of the study
and the publication of the secondary outcome measures is still
pending. The results of one trial (Dubois 2007) are only available
in poster format and, due to the very limited details provided,
only one of the efficacy variables could be included in this meta-
analysis. Despite numerous attempts to contact the authors, no
further details of the trial have been made available.
Other sources of bias
Two trials (Aarsland 2002a; Ravina 2005) were cross-over in de-
sign and were considered in accordance with the guidance of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008). Although dementia is a neuro-degenerative condition, the
duration of the trials was considered to be too short for any signif-
icant disease progression to have occurred in that period. Neither
of the two studies demonstrated a significant carry-over effect be-
tween the two phases of the trial.
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Effects of interventions
Table 1
Global assessment
Three trials comparing cholinesterase inhibitor treatment to
placebo in PDD (Aarsland 2002a; Emre 2004; Ravina 2005) re-
ported a difference in the ADCS-CGIC score of -0.38, favouring
the cholinesterase inhibitors (95% CI -0.56 to -0.24, P < 0.0001)
(Figure 1). A therapeutic benefit of cholinesterase inhibitors was
observed irrespective of the agent used and the duration of the
trial (weighted mean difference (WMD) -0.62, 95% CI -1.13 to -
0.10, P = 0.02 for donepezil used for 10 weeks or less; and WMD
-0.35, 95% CI -0.54 to -0.16, P = 0.0003 for rivastigmine used
for 18 weeks or more).
Figure 1. Forest plot of comparison: 1 Global Assessment, outcome: 1.1 Alzheimer’s Disease Cooperative
Study - Clinician’s Global Impression of Change (ADCS-CGIC).
Three trials reported response rates (Aarsland 2002a; Dubois
2007; Emre 2004). These favoured the cholinesterase inhibitor
(OR 2.26, 95% CI 1.04 to 4.91, P = 0.04) but with high hetero-
geneity (I2 = 78%).
Cognitive function
Although there was no statistically significant difference in the
MMSE between the control and treatment group for patients with
DLB (McKeith 2000) (WMD 1.24, 95% CI 0.28 to 2.76, P
= 0.11), a beneficial treatment effect was seen in PDD patients
(Aarsland 2002a; Emre 2004; Ravina 2005) (WMD 1.09, 95%
CI 0.45 to 1.73, P = 0.0008) and in PDD and CIND-PD patients
(Aarsland 2002a; Emre 2004; Leroi 2004; Ravina 2005) (WMD
1.05, 95% CI 0.42 to 1.68, P = 0.001). Pooling all available data
showed an improvement in the MMSE favouring treatment with
cholinesterase inhibitors (WMD 1.08, 95% CI 0.50 to 1.66, P
= 0.0003). Furthermore, cholinesterase inhibitors lead to an im-
provement in cognitive function in patients with PDD, as mea-
sured by the ADAS-Cog (Dubois 2007; Emre 2004; Ravina 2005)
(WMD -2.72, 95%CI -3.61 to -1.83, P < 0.00001) and theDelis-
Kaplan Executive Function System (Emre 2004) (WMD 2.80,
95%CI 1.47 to 4.13, P < 0.0001). There was also a statistically sig-
nificant improvement in the Trail Making Test A in patients with
PDDorCIND-PD (Leroi 2004) (WMD-71.68, 95%CI -108.44
to -34.92, P = 0.0001). Cholinesterase inhibitor use had no sta-
tistically significant impact on the Mattis Dementia Rating Scale
(MDRS) when used in patients with PDD alone (Emre 2004;
Ravina 2005) (WMD 3.39, CI 95% -4.06 to 10.84, P = 0.37)
or in patients with PDD or CIND-PD (Emre 2004; Leroi 2004;
Ravina 2005) (WMD 3.70, 95% CI -1.13 to 8.54, P = 0.30). No
significant difference between the two groups was observed using
the Cognitive Drug Research Computerized Assessment system
power of attention scale (Emre 2004) (WMD -173.70, 95% CI -
471.23 to 123.83, P = 0.25), the Ten Point Clock Drawing Test
(Emre 2004) (WMD 1.10, 95% CI -0.01 to 2.21, P = 0.05), Brief
Test of Attention (Leroi 2004) (WMD 1.65, 95% CI -0.82 to
4.12, P = 0.19), Trail Making Test B (Leroi 2004) (WMD -87.24,
95% CI -202.89 to 28.41, P = 0.14), Verbal Fluency Test (Leroi
2004) (WMD 6.63, 95% CI -2.33 to 15.59, P = 0.15), Hopkins
Verbal Learning Test (Leroi 2004) (WMD 1.72, 95% CI -2.93
8Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease
(Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to 6.37, P = 0.47) and the Developmental Test of Visual-Motor
Integration (Leroi 2004) (WMD 0.03, 95% CI -3.28 to 3.34, P
= 0.99).
In an overall assessment of the cognitive function domain, com-
biningMMSE scores where available, and ADASCog scores where
not, the pooled estimate of the effect of cholinesterase inhibitors
on cognitive function measures was consistent with the presence
of a therapeutic benefit (standardised mean difference (SMD) -
0.34, 95% CI -0.46 to -0.23, P < 0.00001) (Figure 2). The bene-
ficial effect of cholinesterase inhibitors on cognitive function was
observed in both the donepezil and rivastigmine groups (SMD -
0.42, 95% CI -0.58 to -0.25, P < 0.00001; SMD -0.27, 95% CI
-0.44 to -0.11, P < 0.001, respectively).
Figure 2. Forest plot of comparison: 2 Cognitive function, outcome: 2.3 Combined: MMSE or ADASCog.
Behavioural disturbance
Analysis of the pooled continuous data relating to behavioural
disturbance rating scales once again favoured treatment with
cholinesterase inhibitors (SMD -0.20, 95% CI -0.36 to -0.04, P =
0.01) (Figure 3). This effect was only seen in trials using rivastig-
mine (SMD -0.21, 95% CI -0.36 to -0.06, P = 0.006) and those
lasting 18 weeks or longer (SMD -0.21, 95% CI -0.36 to -0.06, P
= 0.005). Breakdown of the individual rating scales did not reveal
any effect of the treatment on the Brief Psychiatric Rating Scale
(Ravina 2005) (WMD -0.30, 95% CI -5.89 to 5.25, P = 0.92) or
the 12-item Neuropsychiatric Inventory (Leroi 2004) (WMD -
3.30, 95% CI -13.75 to 7.15, P = 0.54). Patients with DLB failed
to improve their NPI-4 (McKeith 2000) (WMD -1.65, 95% CI -
4.33 to 1.03, P = 0.23) or NPI-10 (McKeith 2000) (WMD -3.30,
95% CI -8.14 to 1.54, P = 0.18) scores on active treatment. Emre
2004 showed an improvement of -2.00 (95% CI -3.91 to -0.09,
P = 0.04) in NPI-10 in PDD patients treated with cholinesterase
inhibitors. Hallucinations were less frequently reported in the ac-
tive treatment group than the placebo group, however this was not
statistically significant (Dubois 2007; Emre 2004) (46/739 versus
33/352; OR 0.64, 95% CI 0.40 to 1.02, P = 0.06). There was
a risk of bias due to selective reporting of this outcome, which
was not available from the large Dubois 2007 study and Aarsland
2002a.
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Figure 3. Forest plot of comparison: 3 Behavioural Disturbance, outcome: 3.5 Combined.
Activities of daily living
There was an improvement in the Alzheimer’sDisease Cooperative
Study activities of daily living rating scale (Emre 2004) (WMD
2.50, 95% CI 0.43 to 4.57, P = 0.02), with no difference observed
using theUPDRS activities of daily living rating scale (Leroi 2004)
(WMD 0.84, 95% CI -6.24 to 7.92, P = 0.82). Combined data
favoured treatment with cholinesterase inhibitors (SMD -0.20,
95% CI -0.38 to -0.02, P = 0.03).
Safety and tolerability
Both the total number of dropouts and the number of dropouts
due to adverse events were significantly higher in the treatment
group as compared to the patients receiving placebo (128/465
versus 45/279; OR 1.94, 95% CI 1.33 to 2.84, P = 0.0006 and
73/430 versus 22/247; OR 2.12, 95%CI 1.27 to 3.55, P = 0.004).
The placebo group experienced significantly fewer adverse events
(668/842 versus 318/452; OR 1.64, 95% CI 1.26 to 2.15, P =
0.0003), although the number of adverse events that were judged
to be severe was not significantly different between the two groups
(21/73 versus 15/73; OR 1.60, 95% CI 0.68 to 3.81, P = 0.28).
Interestingly, the increase in the number of dropouts and adverse
events in the treatment group were significant in studies using
rivastigmine (117/421 versus 42/240; OR 1.82, 95% CI 1.22 to
2.71, P = 0.003 and 357/421 versus 173/240; OR 2.28, 95%
CI 1.53 to 3.38, P < 0.0001, respectively) but not in the studies
using donepezil (11/44 versus 3/39; OR 3.64, 95% CI 0.99 to
13.46, P = 0.05 and 311/421 versus 145/212; OR 1.24, 95% CI
0.86 to 1.80, P = 0.25, respectively). Parkinsonian symptoms were
reported more commonly in the treatment group (139/739 versus
40/352; OR 1.88, 95% CI 1.28 to 2.75, P = 0.001), however this
did not have a significant impact on the UPDRS (total andmotor)
scores (SMD -0.07, 95% CI -0.42 to 0.29, P = 0.71) (Figure 4).
Although tremor was more commonly reported in the treatment
groups (64/739 versus 12/352; OR 2.71, 95% CI 1.44 to 5.09,
P = 0.002), the same was not true of falls (43/739 versus 16/352;
OR 1.29, 95% CI 0.72 to 2.33, P = 0.39). Fewer deaths occurred
in the treatment group when compared to the placebo group (4/
465 versus 9/279; OR 0.28, 95% CI 0.09 to 0.84, P = 0.03).
10Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease
(Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Forest plot of comparison: 5 Safety and Tolerability, outcome: 5.9 Unified Parkinson’s Disease
Rating Scale (UPDRS).
D I S C U S S I O N
We identified six trials to help us to assess the efficacy, safety and
tolerability of cholinesterase inhibitors in dementia with Lewy
bodies (DLB), Parkinson’s disease with dementia (PDD) and cog-
nitive impairment in Parkinson’s disease (CIND-PD).Where pos-
sible, we considered outcome measures for the separate diseases as
well as combining the data available to estimate the general effect
of cholinesterase inhibitors on Lewy body disease.
Currently available evidence suggests that cholinesterase inhibitors
improve global assessment measures in patients with PDD, with
no data for DLB and CIND-PD being available. As there was no
evidence of a positive impact of cholinesterase inhibitors on cogni-
tive function and behavioural disturbance rating scales in patients
with DLB, the overall response in favour of using cholinesterase
inhibitors is likely to be due to the effect seen in patients with
PDD. As only one of the six trials included in this meta-analysis
randomised patients with DLB, the over-representation of patents
with PDD could have a substantial effect on the overall effects.
The effect of cholinesterase inhibitors on measures of activities
of daily living was not assessed in the DLB population but was
statistically significant in the very small trial which included both
patients with PDD and CIND-PD.
The trials that were included provided evidence that cholinesterase
inhibitors were not as well tolerated as placebo, with significantly
more adverse effects and dropouts seen in the active treatment
group. Reassuringly, the frequency of severe adverse effects was
the same in both groups. Indeed, death rates were lower amongst
those taking the active drug than placebo, though this is based
on small numbers. Although parkinsonian symptoms, and tremor
in particular, were reported more frequently as adverse effects in
patients receiving cholinesterase inhibitors, this did not seem to
have an impact on the Parkinson’s disease severity rating scales.
An important limitation of the current study lies in the incomplete
public presentationof data from the importantDubois 2007 study,
which was sponsored by Pfizer. The study was completed prior to
current US legislation on trial registration.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The currently available evidence supports the use of cholinesterase
inhibitors in patient with PDD and CIND-PD, with a positive
impact on global assessment, cognitive function, behavioural dis-
turbance and activities of daily living rating scales. The effect of
cholinesterase inhibitors on patients with DLB has only been in-
vestigated in one small study and, therefore, evidence for their use
in this patient group is less clear.
Implications for research
Patients with DLB were under-represented in this meta-analysis
and further randomised evidence is required to reduce the uncer-
tainty of the effects that cholinesterase inhibitors have in this pa-
tient group. A large trial of donepezil in patients with CIND-PD
is due to commence in 2012 (Burn 2009).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aarsland 2002a
Methods Randomised, single centre, double-blind, cross-over, placebo-controlled.
Duration: 10 weeks.
Participants Country: Norway
No. of centres: 1
Diagnosis: definite or probable PD as per Larsen (Clinical diagnosis of Parkinson’s dis-
ease. Proposal of diagnostic subgroups classified at different levels of confidence) AND
dementia due to PD by DSM-IV criteria.
Inclusions: age 41-95 years,mild-severe Parkinsonism (Hoehn andYahr stage <5), clinical
evidence of decline in memory AND at least one other category of cognitive function
(starting at least 1 year after onset of parkinsonism), MMSE 16-26, on stable regimen
anti-Parkinsonian mediation for at least 1 month immediately preceding study and
throughout its duration, patient accompanied by care-giver (= informant).
Exclusions: brain disease except PD, other severemedical disorders, use of anticholinergic
drugs or psychtropic drugs with anticholinergic effects, use benzodiazepine medication
(except short-acting) in 24 hours before testing
Number of patients: 14
Interventions Route: oral
Treatment: donepezil started at 5mg once daily for 6 weeks and increased to 10mg daily
for 4 weeks if tolerated
Outcomes Primary outcome measures: mini-mental state examination (MMSE), the clinician’s in-
terview based global impression of change (CIBIC+), the motor subscale of the unified
Parkinson’s disease rating scale (UPDRS)
Secondary measures: Neuropsychiatric Inventory (NPI) and the severity of parkinsonism
(rated by patient and informer)
Notes Details of secondary outcome measures are currently unpublished
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a randomisation list was computer
generated according to a random block de-
sign”
Allocation concealment (selection bias) Low risk Quote: “the principal investigator was
given a sealed envelope containing the indi-
vidual treatment regimens of each patient”
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’The initial dose was donepezil 5 mg or
identically appearing placebo tablets taken
once a day in the evening. The dose was
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Aarsland 2002a (Continued)
increased to 10 mg after six weeks if well
tolerated.’
Incomplete outcome data (attrition bias)
All outcomes
High risk Imputation of missing data using LOCF.
Too small to be able to say whether there
was differential dropout in drug arm. The
lack of a published behavioural outcome
increases the risk that there is selective re-
porting bias
Other bias High risk Small pilot studies such as this are inher-
ently at high risk of bias
Dubois 2007
Methods Randomised, multi-centre, double-blind, placebo-controlled, 3-arm parallel group
Duration: 24 weeks
Participants Countries: Details not available
No. of centres: Details not available
Diagnosis: PD by UK Brain Bank Criteria AND dementia by DSM-IV
Inclusions: Mild-moderately severe dementia , MMSE 10-26, present at least 1 year after
onset of PD
Exclusions: Details not available
Number of patients: 550 (377 on active treatment)
Interventions Route: oral
Treatment: donepezil 5mg or 10mg for 24 weeks
Outcomes Primary outcome measures: Alzheimer’s Disease Assessment Scale - Cognitive subscale
(ADAS-Cog); Alzheimer’s Disease Cooperative Study - Clinician’s Global Impression of
Change (ADCS-CGIC)
Secondary outcome measures: executive function tests, working memory, attention and
visuospatial function tests
Notes Tolerability and safety assessed
Treatment-related motor impairment assessed by motor subscale of UPDSRS
Treatment-by-country interaction investigated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation process avail-
able
Allocation concealment (selection bias) Unclear risk No details of available
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Dubois 2007 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details available
Incomplete outcome data (attrition bias)
All outcomes
High risk Only available as a poster. High risk of se-
lective reporting of data, especially given
that remains unpublished
Emre 2004
Methods Randomised, multicenter, double-blind, placebo-controlled.
Duration: 24 weeks
Participants Countries: Austria, Belgium, Canada, France, Germany, Italy, Holland, Norway, Portu-
gal, Spain, Turkey, UK.
No. of centres: not stated.
Diagnosis: PD by UK Parkinson’s Disease Society Brain Bank criteria; Dementia by
DSM-IV (dementia due to Parkinson’s disease code 294.1)
Inclusions: MMSE 10 to 24; onset of symptoms of dementia more than 2 years after
diagnosis of PD; regular caregiver.
Exclusions: primary neurodegenerative disease other than PD or dementia; history ma-
jor depression; presence of active uncontrolled seizure disorder; disability or unstable
disease unrelated to PD; hypersensitivity rivastigmine or similar drugs; use cholinesterase
inhibitor or anticholinergic drug.
Number of patients (Randomised/ITT/completers): rivastigmine: 362/329/263;
placebo:179/161/147
Interventions Route: oral
Treatment: rivastigmine commenced at 1.5mg twice daily and increased according to
tolerability by 3mg daily at intervals of at least 4 weeks over a 16 week period
Outcomes Primary outcome measures: Intention to treat analysis with LOCF
Alzheimer’s Disease Assessment Scale - Cognitive sub-scale (ADAS-Cog); Alzheimer’s
Disease Cooperative Study - Clinician’s Global Impression of Change (ADCS-CGIC)
Secondary measures:Mini-Mental State Examination (MMSE); Alzheimer’sDisease Co-
operative Study - Activities of Daily Living (ADCS-ADL); Neuropsychiatric Inventory
(NPI); Cognitive Drug Research (CDR) Computerized Assessment System power of
attention tests; Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency test;
Ten Point Clock-Drawing test; Unified Parkinson’s Disease Rating Scale (UPDRS)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Emre 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “automated random assignment of
treatment was performed with the use of
a validated system, managed by Novartis
Drug Supply Managment”
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis with LOCF.
About half those who discontinued drug
continued to attend for ITT evaluations,
thereby reducing the attrition bias towards
a positive effect of drug which would be
associated with the greater discontinuation
rate amongst those taking drug which oc-
curred
Other bias Low risk Comment: The study appears to be free of
other sources of bias
Leroi 2004
Methods Randomized, multicenter, double-blind, placebo-controlled.
Duration: 18 weeks
Participants Country: USA
No. of centres: 2
Diagnosis: PD by UK Parkinson’s Disease Brain Bank Criteria AND either dementia or
cognitive impairment secondary to PD by DSM IV
Inclusions: on stable regimens of anti-Parkinsonian medications.
Exclusions: MMSE<10, substance abuse or dependence (by DSM IV criteria), severe
cardiac disease, severe renal disease, severe vascular disease, non-ambulatory, known
inability to tolerate donepezil
Number of patient: 16 (9 on active treatment)
Interventions Route: oral
Treatment: donepezil started at 2.5mg daily for 5 days then 5mg daily for 30 days then
7.5 mg daily for 5 days then 10mg daily for 91 days (total 18 weeks), study medication
could be reduced in 2.5 mg decrements in response to adverse effects
Outcomes LOCF analysis. Primary outcome measure: Mini Mental State Examination (MMSE);
Dementia Rating Scale (DRS) - total score, attention subscore, initiation-perseveration
subscore, conceptualisation subscore, memory subscore; Brief Test of Attention (BTA)
;TrailMaking Test-Part A and B (TMT-A and TMT-B); Verbal Fluency; Hopkins Verbal
Learning Test-Revised (HVLT); Developmental Test of Visual-motor Integration (VMI)
Secondary measures: Neuropsychiatric Inventory (NPI); Cornell Scale for Depression
in Dementia (CSDD); UPDRS-Activities of Daily Living (ADL) and Complications of
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Leroi 2004 (Continued)
Therapy subscales
Safety measures: Unified Parkinson’s Disease Rating Scale (UPDRS) motor subscale;
Hoehn and Yahr stage
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Quote: “the pharmacy maintained the ran-
domisation code”
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
High risk The high dropout rate (>30%), which was
due tomore adverse effects in the drug arm,
and LOCF analysis, combine to create a
high risk of bias towards finding a positive
effect of drug
Other bias High risk This was a small pilot study. Such studies
are inherently at risk of bias
McKeith 2000
Methods Randomised, multicenter, double-blind, placebo-controlled.
Duration: 23 weeks - 20 weeks treatment followed by 3 weeks ’rest’
Participants Countries: Spain, UK and Italy
No. of centres: details not available
Diagnosis: clinical diagnosis of probable Lewy body dementia
Inclusion: MMSE >9, regular caregiver
Exclusion: severe extrapyramidal symptoms, asthma, taking neuroleptics, anticholiner-
gics, selegiline or similar drugs
Number of patients (Randomised/ITT/Completers): RVS: 59/n1/41 Placebo: 61/n2/51
(n1+n2=117)
Interventions Route: oral
Treatment: rivastigmine started at 1.5 mg twice daily, titrated to 6mg twice daily (or
maximum tolerated) over 8 weeks maximum
Outcomes ITT Neuropsychiatric Inventory, 10 and 4 item versions (NPI-10 & NPI-4); speed of
response to selected tests; Clinician’s Global Impression of Change (ADCS-CGIC); Mini
Mental State Examination (MMSE); Unified Parkinson’s Disease Rating Scale (UPDRS)
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McKeith 2000 (Continued)
Notes Data on speed of response was not used in this Cochrane review, as we viewed it as a
proxy measure rather than a direct measure of a clinically important feature of DLB.
We were unable to include the UPDRS, as data was not presented in the published paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation list was computer
generated with a proprietary computer ap-
plication, according to a randomised block
design”
Allocation concealment (selection bias) Low risk Quote: “envelopes were to be opened only
in case of emergency and were collected af-
ter unblinding and verified for code breaks”
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The presentation of ITT, LOCF and OC
data is commendable. However, it is not
reported how many of those in the ITT
dataset were providing data for the final
time point despite having discontinued
medication and whether there was an im-
balance in this. It is not clear whether out-
come reporting was selective
Other bias Low risk Comment: The study appears to be free of
other sources of bias
Ravina 2005
Methods Randomized, multicenter, double-blind, crossover, placebo-controlled.
Duration: 10 weeks
Participants Country: USA
No. of centres: 4
Diagnosis: PDbyMovementDisorders Society Scientific issuesCommittee Parkinsonian
disorders (diagnosis made by movement disorder specialists)
Inclusions: age >40 years, mild-moderate dementia according to DSM IV criteria for
dementia AND MMSE 17-26
Exclusions: clinical diagnosis of DLB, other causes of dementia (e.g. stoke), use of
cholinergic or anticholinergic agents except amantadine or tolterodine within 2 weeks
before screening, medical conditions or uncontrolled psychosis which were thought by
investigator to interfere with the safe conduct of study, pregnancy or lactation.
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Ravina 2005 (Continued)
Number of patients: 22
Interventions Route: oral
Treatment: donepezil started at 5mg once daily and increased according to tolerability
to donepezil 5mg twice daily after 3 weeks, then continued at that dose (if tolerated,
otherwise reduced back to 5mg once daily) for 6 weeks
Outcomes Primary outcome measure: Alzheimer’s Disease Assessment Scale-Cognitive Subscale
(ADAS-Cog)
Secondarymeasures: MiniMental State Examination (MMSE);Mattis Dementia Rating
Scale (MDRS); Brief PsychiatricRating Scale (BPRS);UnifiedParkinson’sDiseaseRating
Scale (UPDRS); Clinician’s Global Impression of Change (ADCS-CGIC)
Notes Data from first 10 week period was analysed for this review
BPRS is a measure of psychosis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Drug distribution to the sites and ran-
domisation were performed by the Univer-
sity of Pennsylvania
Investigational Drug Services Unit. Sub-
jects were randomised in blocks of four
to receive either donepezil in period I and
placebo in period II or placebo in period I
and donepezil in period II.’
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’matching placebo’
Incomplete outcome data (attrition bias)
All outcomes
High risk LOCF imputation of missing data
Other bias High risk This was a very small study. Such studies
are at inherent risk of bias
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aarsland 2002 Open label study
Adler 2011 Non-interventional trial
Anand 2000 Conference presentation. Review, not a clinical trial
Barone 2008 Only hyperhomocysteinemic Parkinson’s disease dementia patients included
Barone 2010 Open label study
Bergman 2002 Open label study
Bergman 2003 Open label study; trial of people with Alzheimer’s disease, not Parkinson’s
Beversdorf 2004 Data kindly provided by the author, judged unsuitable for meta-analysis as a small double cross-over study
without a wash-out period and no carry-over effect analysis
Brashear 2004 Data limited, details not available
Chung 2010 Trial of people with Parkinson’s disease with advanced postural instability
Cummings 2010 Trial of people with Alzheimer’s disease, not Parkinson’s
De Deyn 2011 Open label study
Fabbrini 2002 Open label study
Fogelson 2003 Open label study; non-standard outcome measures
Foy 2000 Diagnostic criteria outside specification
Fujita 2010 Case report
Giladi 2003 Open label study
Gustavsson 2009 Open label study
Hutchinson 1996 Open label study
Korczyn 2001 Open label study
Lanctot 2000 Case series
Linsarazo 2005 Open label study
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(Continued)
Litvinenko 2008 Open label study
McKeith 2000a Open label exploratory trial; 20 weeks active treatment then 6 weeks of withdrawal
McLaren 2003 Open label study
Minett 2003 Open label study
Mori 2006 Open label study
Olin 2010a Open label study, rivastigmine and memantine used
Pakrasi 2006 Open label study
Reading 2001 Open label study
Rektorova 2004 Open label study
Rosengarten 2010 Investigation of pathophysiological changes
Samuel 2000 Lewy body dementia patients compared with Alzheimer’s disease patients regarding response to donepezil
Satoh 2010 Investigation of pathophysiological changes
Thomas 2005 Open label study
Touchon 2006a Retrospective study
Touchon 2006b as Touchon 2006a
Van Laar 2001 Open label study
Vasile 2010a Comparative efficacy of cholinesterase inhibitors, no placebo group
Vasile 2010b Comparative efficacy of cholinesterase inhibitors, no placebo group
Walker 2000b Investigation of pathophysiological changes
Werber 2001 Open label study
Wilcock 2000 Project abandoned
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Characteristics of ongoing studies [ordered by study ID]
Anon 2004a
Trial name or title Donepezil for dementia in Parkinson’s disease: A randomised double blinded placebo controlled crossover
trial
Methods RCT
Participants N = 28
Country = USA
Duration = 26 weeks
Interventions Donepezil + Placebos
Outcomes -ADAS/cog
-cognitive function
-activities of daily living
-mood
-quality of life
-side effects
-motor performance
Starting date February 2002
Contact information
Notes Study ID numbers 020115; 02-N-0115//NLM identifier NCT00030979
Anon 2007a
Trial name or title Double-blind study of E2020 in patients with dementia with Lewy bodies - Phase II
Methods RCT
Participants N = 160
Country = Japan
Duration = 12 weeks
Interventions Donepezil (E2020), Dosage of drug, Placebo
Outcomes Primary outcome measures: Cognitive function, psychiatric symptoms, and global clinical function, burden
on caregiver at 12 weeks
Starting date November 2007
Contact information
Notes Study ID(s) and Acronym(s): NCT00543855 // E2020-J081-431
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Anon 2011
Trial name or title A study of E2020 in patients with dementia with Lewy bodies (DLB), followed by a long-term extension
phase - Phase III
Methods RTC
Participants N = 141
Country = Japan
Duration = 52 weeks
Interventions Donepezil (E2020), Dosage of drug, Placebo
Outcomes Primary Outcome Measures: Change from baseline in Mini Mental State Examination and Neuropsychiatric
Inventory after 12 weeks
Starting date February 2011
Contact information
Notes Study ID(s) and Acronym(s): NCT01278407 // E2020-J081-341
Burn 2009
Trial name or title Multi-centre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with
Parkinson’s disease (MUSTARDD-PD)
Methods - RCT
- 1. Donepezil: Experimental - 5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient
adjusted to 5mg dose. 10mg does continues for the remainder of the study; 2. Placebo: Placebo Comparator
- Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the
remainder of the study
Participants N = 500
Country = UK
Duration = 24 months
Interventions Donepezil, Placebo
Outcomes Primary OutcomeMeasures: To demonstrate the superiority of donepezil over placebo in improving cognitive
function, neuropsychiatric burden and functional ability in people with Parkinson’s disease andmild dementia
after 24 months of treatment
Secondary OutcomeMeasures: To demonstrate the superiority of donepezil over placebo in improving patient
and carer quality of life and to establish the cost-effectiveness of donepezil
Starting date March 2010
Contact information
Notes Study ID(s) and Acronym(s): NCT01014858 // MUSTARDD-PD // 5137 // 08/13/14
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Kurlan 2003
Trial name or title Treatment of agitation/psychosis in dementia/parkinsonism
Methods
Participants N = Unknown
Country = USA
Duration = Unknown
Interventions Donepezil, Quetiapine, Dosage of drug
Outcomes Unknown
Starting date
Contact information Kurlan R Treatment of agitation/psychosis in dementia/parkinsonism Alzheimer’s Disease Education and
Referral Center (ADEAR) 2003
Notes
Marion 2003
Trial name or title An open 24 week prospective, randomised, double-blind placebo controlled parallel group study of efficacy,
tolerability and safety of 3-12mg/day of Exelon and Exelon (rivastigmine) capsules in patients with Parkinson’s
disease dementia
Methods
Participants N = 10
Country = UK
Duration = 24 weeks
Interventions Rivastigmine + Dosage of Drug + Placebos
Outcomes Unclear
Starting date
Contact information Marie-Helene.Marion@stgeorges.nhs.uk
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Global assessment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Alzheimer’s Disease Cooperative
Study - Clinician’s Global
Impression of Change (ADCS-
CGIC)
3 556 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.56, -0.20]
2 Clinical Global Responder - at
least minimal improvement
3 785 Odds Ratio (M-H, Random, 95% CI) 2.26 [1.04, 4.91]
Comparison 2. Cognitive function
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mini Mental State Examination 5 699 Mean Difference (IV, Fixed, 95% CI) 1.08 [0.50, 1.66]
2 Alzheimer’s Disease Assessment
Scale (ADAS-cog)
3 1078 Mean Difference (IV, Fixed, 95% CI) -2.72 [-3.61, -1.83]
3 Combined: MMSE or
ADASCog
6 1249 Std. Mean Difference (IV, Random, 95% CI) 0.34 [0.23, 0.46]
4 Mattis Dementia Rating Scale
(MDRS)
3 82 Mean Difference (IV, Fixed, 95% CI) 3.70 [-1.13, 8.54]
5 Cognitive Drug Research (CDR)
computerised assessment
system power of attention
1 486 Mean Difference (IV, Fixed, 95% CI) -173.7 [-471.23,
123.83]
6 Delis-Kaplan Executive Function
System (D-KEFS)
1 402 Mean Difference (IV, Fixed, 95% CI) 2.8 [1.47, 4.13]
7 Ten Point Clock Drawing Test 1 79 Mean Difference (IV, Fixed, 95% CI) 1.1 [-0.01, 2.21]
8 Brief Test of Attention (BTA) 1 16 Mean Difference (IV, Fixed, 95% CI) 1.65 [-0.82, 4.12]
9 Trail Making Test (TMT) A 1 16 Mean Difference (IV, Fixed, 95% CI) -71.68 [-108.44, -
34.92]
10 Trail Making Test (TMT) B 1 16 Mean Difference (IV, Fixed, 95% CI) -87.24 [-202.89, 28.
41]
11 Verbal Fluency Test 1 16 Mean Difference (IV, Fixed, 95% CI) 6.63 [-2.33, 15.59]
12 Hopkins Verbal Learning Test 1 16 Mean Difference (IV, Fixed, 95% CI) 1.72 [-2.93, 6.37]
13 Developmental Test of Visual-
Motor Integration (VMI)
1 16 Mean Difference (IV, Fixed, 95% CI) 0.03 [-3.28, 3.34]
30Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease
(Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 3. Behavioural disturbance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 12-item Neuropsychiatric
Inventory (NPI-12)
1 16 Mean Difference (IV, Fixed, 95% CI) -3.3 [-13.75, 7.15]
2 10-item Neuropsychiatric
Inventory (NPI-10)
2 620 Mean Difference (IV, Fixed, 95% CI) -2.18 [-3.95, -0.40]
3 4-item Neuropsychiatric
Inventory (NPI-4)
1 120 Mean Difference (IV, Fixed, 95% CI) -1.66 [-4.34, 1.02]
4 Brief Psychiatric Rating Scale 1 38 Mean Difference (IV, Fixed, 95% CI) -0.30 [-5.89, 5.29]
5 Combined 4 674 Std. Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.36, -0.04]
5.1 12-item Neuropsychiatric
Inventory (NPI-12)
1 16 Std. Mean Difference (IV, Fixed, 95% CI) -0.29 [-1.29, 0.70]
5.2 10-item Neuropsychiatric
Inventory (NPI-10)
2 620 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.37, -0.04]
5.3 Brief Psychiatric Rating
Scale
1 38 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.67, 0.60]
Comparison 4. Activities of daily living
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Alzheimer’s Disease Cooperative
Study - Activities of Daily
Living (ADCS-ADL)
1 498 Mean Difference (IV, Fixed, 95% CI) 2.5 [0.43, 4.57]
2 Unified Parkinson’s Disease
Rating Scale (UPDRS) -
Activities of Daily Living
1 16 Mean Difference (IV, Fixed, 95% CI) 0.84 [-6.24, 7.92]
3 Combined 2 514 Std. Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.38, -0.02]
3.1 Alzheimer’s Disease
Cooperative Study - Activities
of Daily Living (ADCS-ADL)
1 498 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.40, -0.02]
3.2 Unified Parkinson’s
Disease Rating Scale (UPDRS)
- Activities of Daily Living
1 16 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.88, 1.10]
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Comparison 5. Safety and tolerability
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dropouts 5 744 Odds Ratio (M-H, Fixed, 95% CI) 1.94 [1.33, 2.84]
2 Dropouts due to Adverse Events 3 677 Odds Ratio (M-H, Fixed, 95% CI) 2.12 [1.27, 3.55]
3 Adverse Events 6 1294 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [1.26, 2.15]
4 Severe Adverse Events 2 146 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.68, 3.81]
5 Parkinsonian symptoms reported
as adverse effects
2 1091 Odds Ratio (M-H, Fixed, 95% CI) 1.88 [1.28, 2.75]
6 Tremor 2 1091 Odds Ratio (M-H, Fixed, 95% CI) 2.71 [1.44, 5.09]
7 Falls 2 1091 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.72, 2.33]
8 Hallucinations 2 1091 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.40, 1.02]
9 Unified Parkinson’s Disease
Rating Scale (UPDRS)
3 122 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.42, 0.29]
9.1 Motor 3 81 Std. Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.49, 0.39]
9.2 Total 1 41 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.72, 0.51]
10 Deaths 5 744 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.09, 0.84]
A D D I T I O N A L T A B L E S
Table 1. Effect of cholinesterase inhibitors on dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impair-
ment in Parkinson’s disease
Dementia with Lewy
Bodies(DLB)
Parkinson’s Disease
with dementia (PDD)
Parkinson’s
Disease with dementia
(PDD) and cognitive
impairment in Parkin-
son’s Disease (CIND-
PD)
Pooled results for
DLB/PDD/CIND-PD
Global Assessment N/A Favours treatment
(SMD -0.38, 95% CI -
0.56, -0.24, P<0.00001)
N/A N/A
Cognitive Function No effect
(SMD -0.29, 95% CI -
0.65, 0.07, P=0.12)
Favours treatment
(SMD -0.36, 95% CI -
0.48, -0.23, P<0.00001)
Favours treatment
(SMD -0.36, 95% CI -
0.48, -0.23, P<0.00001)
Favours treatment
(SMD -0.34, 95% CI -
0.46, -0.23, P<0.00001)
Behavioural
Disturbance
No effect
(SMD -0.24, 95% CI -
0.60, 0.12, P=0.19)
Favours treatment
(SMD -0.18, 95% CI -
0.36, -0.01, P=0.04)
Favours treatment
(SMD -0.19, 95% CI -
0.36, -0.01, P=0.04)
Favours treatment
(SMD -0.20, 95% CI -
0.36, -0.04, P=0.01)
Activities of Daily Liv-
ing
N/A Favours treatment
(SMD -0.21, 95% CI -
0.40, -0.02, P=0.03)
Favours treatment
(SMD -0.20, 95% CI -
0.39, -0.02, P=0.03)
N/A
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WH A T ’ S N E W
Last assessed as up-to-date: 30 August 2011.
Date Event Description
30 August 2011 Amended A pre-publication search was performed for this review on 30 August 2011 to ensure the review was
as up-to-date as possible before publication
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 3, 2012
Date Event Description
8 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
MR extracted the data, did the analysis and wrote the current draft. CF and IM contributed to previous versions of the review and
commented on the current draft. RMwrote the first draft of this new title, was responsible for design and contributed to data extraction,
interpretation, analysis and redrafting.
D E C L A R A T I O N S O F I N T E R E S T
RMcS has received financial support to attend conferences from Eisai, Shire and Novartis, all marketers of cholinesterase inhibitors,
more than five years ago. Within the last two years, his institution has received funding for his activities as a local PL for a Novartis
study of rivastigmine patch versus tablets in Parkinson’s disease dementia.
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Medical Subject Headings (MeSH)
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etiology]; Indans [adverse effects; therapeutic use]; Lewy Body Disease [∗drug therapy]; Neuroprotective Agents [adverse effects;
therapeutic use]; Parkinson Disease [∗complications]; Phenylcarbamates [adverse effects; therapeutic use]; Piperidines [adverse effects;
therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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